DE60322665D1 - Pharmazeutische darreichungsform mit gesteuerter freigabe eines cholesterylester-transferproteininhibitors - Google Patents

Pharmazeutische darreichungsform mit gesteuerter freigabe eines cholesterylester-transferproteininhibitors

Info

Publication number
DE60322665D1
DE60322665D1 DE60322665T DE60322665T DE60322665D1 DE 60322665 D1 DE60322665 D1 DE 60322665D1 DE 60322665 T DE60322665 T DE 60322665T DE 60322665 T DE60322665 T DE 60322665T DE 60322665 D1 DE60322665 D1 DE 60322665D1
Authority
DE
Germany
Prior art keywords
pharmaceutical
cholesteryl
controlled release
transfer protein
sample transfer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60322665T
Other languages
English (en)
Inventor
Groton Curatolo
Groton Sutton
Leah Elizabeth Appel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Products Inc
Original Assignee
Pfizer Products Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Inc filed Critical Pfizer Products Inc
Application granted granted Critical
Publication of DE60322665D1 publication Critical patent/DE60322665D1/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/47064-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/02Peptides of undefined number of amino acids; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0002Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1652Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
DE60322665T 2002-02-01 2003-01-20 Pharmazeutische darreichungsform mit gesteuerter freigabe eines cholesterylester-transferproteininhibitors Expired - Fee Related DE60322665D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US35371902P 2002-02-01 2002-02-01
PCT/IB2003/000209 WO2003063868A1 (en) 2002-02-01 2003-01-20 Controlled release pharmaceutical dosage forms of a cholesteryl ester transfer protein inhibitor

Publications (1)

Publication Number Publication Date
DE60322665D1 true DE60322665D1 (de) 2008-09-18

Family

ID=27663244

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60322665T Expired - Fee Related DE60322665D1 (de) 2002-02-01 2003-01-20 Pharmazeutische darreichungsform mit gesteuerter freigabe eines cholesterylester-transferproteininhibitors

Country Status (24)

Country Link
US (1) US20030198674A1 (de)
EP (1) EP1474144B1 (de)
JP (1) JP2005522424A (de)
KR (1) KR20040083493A (de)
CN (1) CN1625397A (de)
AR (1) AR038385A1 (de)
AT (1) ATE403432T1 (de)
BR (1) BR0307332A (de)
CA (1) CA2473991C (de)
DE (1) DE60322665D1 (de)
ES (1) ES2309294T3 (de)
GT (1) GT200300023A (de)
HN (1) HN2003000054A (de)
IL (1) IL162870A0 (de)
MX (1) MXPA04005647A (de)
NO (1) NO20043506L (de)
PA (1) PA8565101A1 (de)
PE (1) PE20030806A1 (de)
PL (1) PL371416A1 (de)
RU (1) RU2004123637A (de)
TW (1) TW200303204A (de)
UY (1) UY27643A1 (de)
WO (1) WO2003063868A1 (de)
ZA (1) ZA200404718B (de)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4865989B2 (ja) 2002-02-01 2012-02-01 ベンド・リサーチ・インコーポレーテッド 改良された噴霧乾燥装置を使用する均質な噴霧乾燥された固体の非晶質薬物分散物を製造する方法
GB0203296D0 (en) 2002-02-12 2002-03-27 Glaxo Group Ltd Novel composition
US8637512B2 (en) 2002-07-29 2014-01-28 Glaxo Group Limited Formulations and method of treatment
US20040122048A1 (en) * 2002-10-11 2004-06-24 Wyeth Holdings Corporation Stabilized pharmaceutical composition containing basic excipients
ES2310676T3 (es) * 2002-12-20 2009-01-16 Pfizer Products Inc. Formas de dosificacion que comprenden un inhibidor de cetp y un inhibidor de hmg-coa reductasa.
WO2004085996A2 (en) * 2003-03-20 2004-10-07 Albert Einstein College Of Medicine Of Yeshiva University Biomarkers for longevity and disease and uses thereof
CL2004001884A1 (es) * 2003-08-04 2005-06-03 Pfizer Prod Inc Procedimiento de secado por pulverizacion para la formacion de dispersiones solidas amorfas de un farmaco y polimeros.
SI1670768T1 (sl) 2003-10-08 2010-01-29 Lilly Co Eli Spojine in metode za zdravljenje dislipidemije
JP2007517015A (ja) * 2003-12-31 2007-06-28 ファイザー・プロダクツ・インク 低溶解性薬物、ポロキサマーおよび安定化ポリマーの安定化された医薬用固体組成物
EP1735320B1 (de) 2004-03-26 2009-06-17 Eli Lilly And Company Verbindungen und verfahren zur behandlung von dyslipidämie
UA90269C2 (ru) 2004-04-02 2010-04-26 Мицубиси Танабе Фарма Корпорейшн Тетрагидрохинолиновые производные и способ их получения
TWI345568B (en) 2004-04-02 2011-07-21 Mitsubishi Tanabe Pharma Corp Tetrahydronaphthyridine derivatives and a process for preparing the same
WO2006069162A1 (en) * 2004-12-20 2006-06-29 Reddy Us Therapeutics, Inc. Novel heterocyclic compounds and their pharmaceutical compositions
CA2605214C (en) * 2004-12-31 2016-07-12 Reddy Us Therapeutics, Inc. Benzylamine derivatives as cetp inhibitors
US8604055B2 (en) * 2004-12-31 2013-12-10 Dr. Reddy's Laboratories Ltd. Substituted benzylamino quinolines as cholesterol ester-transfer protein inhibitors
PT1855652E (pt) * 2005-01-28 2016-01-26 Bend Res Inc Secagem de partículas contendo fármacos
EP1845953A1 (de) * 2005-02-03 2007-10-24 Pfizer Products Incorporated Darreichungsformen mit kontrollierter und unmittelbarer freisetzung von cholesterylester-transferprotein-hemmern und unmittelbarer freisetzung von hmg-coa-reduktase-hemmern
WO2006098394A1 (ja) * 2005-03-14 2006-09-21 Japan Tobacco Inc. 脂質吸収抑制方法および脂質吸収抑制剤
PE20071025A1 (es) 2006-01-31 2007-10-17 Mitsubishi Tanabe Pharma Corp Compuesto amina trisustituido
UY30117A1 (es) 2006-01-31 2007-06-29 Tanabe Seiyaku Co Compuesto amina trisustituido
BRPI0707584A2 (pt) * 2006-02-09 2011-05-10 Merck & Co Inc composiÇço farmacÊutica, uso da composiÇço farmacÊutica, e, formulaÇço farmacÊutica
GB0613925D0 (en) * 2006-07-13 2006-08-23 Unilever Plc Improvements relating to nanodispersions
US8834929B2 (en) * 2006-07-21 2014-09-16 Bend Research, Inc. Drying of drug-containing particles
US7750019B2 (en) 2006-08-11 2010-07-06 Kowa Company, Ltd. Pyrimidine compound having benzyl(pyridylmethyl)amine structure and medicament comprising the same
US20100062073A1 (en) * 2006-11-29 2010-03-11 Ronald Arthur Beyerinck Pharmaceutical compositions comprising nanoparticles comprising enteric polymers casein
WO2008065506A2 (en) * 2006-11-29 2008-06-05 Pfizer Products Inc. Pharmaceutical compositions comprising nanoparticles comprising enteric polymers and casein
US7790737B2 (en) 2007-03-13 2010-09-07 Kowa Company, Ltd. Substituted pyrimidine compounds and their utility as CETP inhibitors
US8900629B2 (en) 2007-04-05 2014-12-02 University Of Kansas Rapidly dissolving pharmaceutical compositions comprising pullulan
JP5379121B2 (ja) * 2007-04-05 2013-12-25 ユニバーシティ・オブ・カンザス プルランを含む速溶性医薬組成物
MX2009010962A (es) 2007-04-13 2009-12-16 Kowa Co Compuesto pirimidina novedoso que tiene estructura de dibencilamina y medicamento que comprende el mismo.
WO2008135855A2 (en) * 2007-05-03 2008-11-13 Pfizer Products Inc. Nanoparticles comprising a cholesteryl ester transfer protein inhibitor and a nonionizable polymer
WO2009023672A2 (en) 2007-08-13 2009-02-19 Abuse Deterrent Pharmaceutical Llc Abuse resistant drugs, method of use and method of making
EP3520776A1 (de) * 2009-06-16 2019-08-07 Pfizer Inc Darreichungsformen von apixaban
JP5964965B2 (ja) 2011-08-18 2016-08-03 ドクター レディズ ラボラトリーズ リミテッド コレステリルエステル転送タンパク質(cetp)インヒビターとしての置換複素環式アミン化合物
IN2014CN02290A (de) 2011-09-27 2015-06-19 Reddys Lab Ltd Dr
US20140275149A1 (en) 2013-03-15 2014-09-18 Inspirion Delivery Technologies, Llc Abuse deterrent compositions and methods of use
KR101610465B1 (ko) * 2014-04-11 2016-04-07 국립암센터 다목적용 의료 영상 표지자 및 이의 제조방법
US10729685B2 (en) 2014-09-15 2020-08-04 Ohemo Life Sciences Inc. Orally administrable compositions and methods of deterring abuse by intranasal administration
CN104474553A (zh) * 2014-11-26 2015-04-01 嘉应学院医学院 一种基于β-谷甾醇的药物缓释剂及其制备方法
CN107098946B (zh) * 2016-02-23 2021-01-29 中国药科大学 Cetp抑制剂的合成与用途
WO2020263560A1 (en) 2019-06-26 2020-12-30 Carrier Corporation Transportation refrigeration unit with adaptive defrost
CA3192982A1 (en) * 2020-09-18 2022-03-24 Umesh KESTUR Dosage forms for tyk2 inhibitors comprising swellable cores

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US54038A (en) * 1866-04-17 Improvement in priming metallic cartridges
US18446A (en) * 1857-10-20 Improvement in steam-plows
US91643A (en) * 1869-06-22 Improvement in gang-plows
US28895A (en) * 1860-06-26 Machine for wetting paper
US3995631A (en) 1971-01-13 1976-12-07 Alza Corporation Osmotic dispenser with means for dispensing active agent responsive to osmotic gradient
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US4247498A (en) 1976-08-30 1981-01-27 Akzona Incorporated Methods for making microporous products
US4564488A (en) 1978-07-31 1986-01-14 Akzo Nv Methods for the preparation of porous fibers and membranes
CA1146866A (en) 1979-07-05 1983-05-24 Yamanouchi Pharmaceutical Co. Ltd. Process for the production of sustained release pharmaceutical composition of solid medical material
US4490431A (en) 1982-11-03 1984-12-25 Akzona Incorporated 0.1 Micron rated polypropylene membrane and method for its preparation
US4612008A (en) 1983-05-11 1986-09-16 Alza Corporation Osmotic device with dual thermodynamic activity
US5225192A (en) 1988-10-17 1993-07-06 Vectorpharma International S.P.A. Poorly soluble medicaments supported on polymer substances in a form suitable for increasing their dissolving rate
DE3438830A1 (de) 1984-10-23 1986-04-30 Rentschler Arzneimittel Nifedipin enthaltende darreichungsform und verfahren zu ihrer herstellung
DE3612212A1 (de) 1986-04-11 1987-10-15 Basf Ag Verfahren zur herstellung von festen pharmazeutischen formen
US5612059A (en) 1988-08-30 1997-03-18 Pfizer Inc. Use of asymmetric membranes in delivery devices
IL92966A (en) 1989-01-12 1995-07-31 Pfizer Hydrogel-operated release devices
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
KR0182801B1 (ko) 1991-04-16 1999-05-01 아만 히데아키 고체 분산체의 제조방법
US5340591A (en) 1992-01-24 1994-08-23 Fujisawa Pharmaceutical Co., Ltd. Method of producing a solid dispersion of the sparingly water-soluble drug, nilvadipine
JP3265680B2 (ja) 1992-03-12 2002-03-11 大正製薬株式会社 経口製剤用組成物
DE4316537A1 (de) 1993-05-18 1994-11-24 Basf Ag Zubereitungen in Form fester Lösungen
DE4327063A1 (de) 1993-08-12 1995-02-16 Kirsten Dr Westesen Ubidecarenon-Partikel mit modifizierten physikochemischen Eigenschaften
US6054136A (en) 1993-09-30 2000-04-25 Gattefosse S.A. Orally administrable composition capable of providing enhanced bioavailability when ingested
US5458887A (en) 1994-03-02 1995-10-17 Andrx Pharmaceuticals, Inc. Controlled release tablet formulation
DE4440337A1 (de) 1994-11-11 1996-05-15 Dds Drug Delivery Services Ges Pharmazeutische Nanosuspensionen zur Arzneistoffapplikation als Systeme mit erhöhter Sättigungslöslichkeit und Lösungsgeschwindigkeit
EP0733061A1 (de) * 1994-11-12 1996-09-25 LG Chemical Limited Peptidinhibitoren des Cholesterylesther - Transferprotein und prophylaktische und therapeutische anti - artheriosklerose Agenten
DE19504832A1 (de) 1995-02-14 1996-08-22 Basf Ag Feste Wirkstoff-Zubereitungen
SI9500173B (sl) 1995-05-19 2002-02-28 Lek, Trofazna farmacevtska oblika s konstantnim in kontroliranim sproščanjem amorfne učinkovine za enkrat dnevno aplikacijo
US5654005A (en) 1995-06-07 1997-08-05 Andrx Pharmaceuticals, Inc. Controlled release formulation having a preformed passageway
US5798119A (en) 1995-06-13 1998-08-25 S. C. Johnson & Son, Inc. Osmotic-delivery devices having vapor-permeable coatings
US5686133A (en) 1996-01-31 1997-11-11 Port Systems, L.L.C. Water soluble pharmaceutical coating and method for producing coated pharmaceuticals
US5993858A (en) 1996-06-14 1999-11-30 Port Systems L.L.C. Method and formulation for increasing the bioavailability of poorly water-soluble drugs
HRP970330B1 (en) * 1996-07-08 2004-06-30 Bayer Ag Cycloalkano pyridines
DE19627431A1 (de) * 1996-07-08 1998-01-15 Bayer Ag Heterocyclisch kondensierte Pyridine
US5874418A (en) 1997-05-05 1999-02-23 Cydex, Inc. Sulfoalkyl ether cyclodextrin based solid pharmaceutical formulations and their use
US6046177A (en) 1997-05-05 2000-04-04 Cydex, Inc. Sulfoalkyl ether cyclodextrin based controlled release solid pharmaceutical formulations
US6197786B1 (en) * 1998-09-17 2001-03-06 Pfizer Inc 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines
GT199900147A (es) * 1998-09-17 1999-09-06 1, 2, 3, 4- tetrahidroquinolinas 2-sustituidas 4-amino sustituidas.
US6140342A (en) * 1998-09-17 2000-10-31 Pfizer Inc. Oxy substituted 4-carboxyamino-2-methyl-1,2,3,4-tetrahydroquinolines
US6147089A (en) * 1998-09-17 2000-11-14 Pfizer Inc. Annulated 4-carboxyamino-2-methyl-1,2,3,4,-tetrahydroquinolines
US6147090A (en) * 1998-09-17 2000-11-14 Pfizer Inc. 4-carboxyamino-2-methyl-1,2,3,4,-tetrahydroquinolines
DE69935992T4 (de) 1998-09-25 2008-05-29 Monsanto Co., Chicago Polycyclische aryl und heteroaryl substituierte tertiäre heteroalkylamine, für die hemmung der aktivität des cholesteryl-ester-transfer-proteins
US6174873B1 (en) * 1998-11-04 2001-01-16 Supergen, Inc. Oral administration of adenosine analogs
EP1027887B1 (de) * 1999-02-10 2008-08-13 Pfizer Products Inc. Vorrichtung mit matrixgesteuerter Wirkstofffreisetzung
US6706283B1 (en) 1999-02-10 2004-03-16 Pfizer Inc Controlled release by extrusion of solid amorphous dispersions of drugs
BR0016708A (pt) * 1999-12-23 2002-10-08 Pfizer Prod Inc Forma de dosagem de droga baseada em hidrogel
SK8562002A3 (en) 1999-12-23 2003-10-07 Pfizer Prod Inc Pharmaceutical compositions providing enhanced drug concentrations
US7115279B2 (en) 2000-08-03 2006-10-03 Curatolo William J Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors
EP1269994A3 (de) 2001-06-22 2003-02-12 Pfizer Products Inc. Pharmazeutische Zusammensetzungen die ein Arzneimittel und die Konzentration verbesserende Polymere enthalten
OA12625A (en) * 2001-06-22 2006-06-12 Pfizer Prod Inc Pharmaceutical compositions of adsorbates of amorphous drug.
JP4644397B2 (ja) * 2001-09-05 2011-03-02 信越化学工業株式会社 難溶性薬物を含む医薬用固形製剤の製造方法
AR038375A1 (es) 2002-02-01 2005-01-12 Pfizer Prod Inc Composiciones farmaceuticas de inhibidores de la proteina de transferencia de esteres de colesterilo

Also Published As

Publication number Publication date
EP1474144A1 (de) 2004-11-10
ATE403432T1 (de) 2008-08-15
CA2473991C (en) 2009-09-15
GT200300023A (es) 2003-09-17
CA2473991A1 (en) 2003-08-07
CN1625397A (zh) 2005-06-08
PE20030806A1 (es) 2003-09-19
KR20040083493A (ko) 2004-10-02
IL162870A0 (en) 2005-11-20
RU2004123637A (ru) 2005-04-20
US20030198674A1 (en) 2003-10-23
MXPA04005647A (es) 2005-03-23
AR038385A1 (es) 2005-01-12
TW200303204A (en) 2003-09-01
ZA200404718B (en) 2006-11-29
NO20043506L (no) 2004-10-19
UY27643A1 (es) 2003-08-29
JP2005522424A (ja) 2005-07-28
WO2003063868A1 (en) 2003-08-07
ES2309294T3 (es) 2008-12-16
PL371416A1 (en) 2005-06-13
BR0307332A (pt) 2004-12-07
EP1474144B1 (de) 2008-08-06
HN2003000054A (es) 2003-11-24
PA8565101A1 (es) 2003-11-12

Similar Documents

Publication Publication Date Title
DE60322665D1 (de) Pharmazeutische darreichungsform mit gesteuerter freigabe eines cholesterylester-transferproteininhibitors
DE60144332D1 (de) Pharmazeutische zusammensetzungen mit cholesteryl ester transfer protein inhibitoren
DE60332393D1 (de) Flüssige pharmazeutische zusammensetzung mit pyridonderivaten
ATE555809T1 (de) Pharmezeutische anti-tnf-alpha antikörper formulierung
NO20055652D0 (no) Laktatinneholdende farmasoytisk preparat og anvendelse av dette
DE602005021475D1 (de) Magenresistente pharmazeutische dosierform mit n-(2-(2-phthalimidoethoxy)-acetyl)-l-alanyl-d-glutaminsäure (lk-423)
IS8401A (is) Fullmanngerð mótefni gegn 4-1BB í mönnum (CD137)
DK1578755T3 (da) Phosphonooxyguinalinderivater og deres farmaceutiske anvendelse
PT1567477E (pt) Ácidos amino fenilacéticos substituídos, seus derivados, sua preparação e seu utilização como inibidores da ciclooxigenase 2 (cox-2)
IS7668A (is) Manngerð mótefni gegn 4-1BB í mönnum
DE60213592D1 (de) Flüssige pharmazeutische zusammensetzung
ATE307571T1 (de) Pharmazeutische formulierung enthaltend bicalutamid
DE60201859D1 (de) Pharmazeutische Verwendung von N-Carbamoylazol-Derivate
ATE309789T1 (de) Darreichungsform von ibuprofen-natrium
DE60305728D1 (de) PHARMAZEUTISCHE ZUSAMMENSETZUNG MIT VERLuNGERTER FREISETZUNG
ATE415949T1 (de) Pharmazeutische formulierung mit levothyroxin- natrium
ATE434435T1 (de) Pharmazeutische zubereitungen enthaltend modafinil
NO20034413D0 (no) Beta-karbolinderivater og deres farmasöytiske anvendelse mot depresjon og angst
DE60217390D1 (de) Bicalutamid enthaltende pharmazeutische zusammensetzung
ATE448780T1 (de) Pharmazeutische modafinil-zusammensetzungen mit modifizierter freisetzung
DE60336999D1 (de) Melatonin enthaltende pharmazeutische formulierung
DE60310526D1 (de) Ivabradin enthaltende pharmazeutische zusammensetzung mit oraler dispersion
ATE438384T1 (de) Matrix-filmtablette mit kontrollierter freisetzung von natürlichen gemischen konjugierter oestrogene
ATE375154T1 (de) Pharmazeutische verwendung von cox-2-hemmern in angiogenese-vermittelten augenerkrankungen
DE10291905D2 (de) Pharmazeutische Zusammensetzung

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee